Q32 Bio Past Earnings Performance
Past criteria checks 3/6
Q32 Bio has been growing earnings at an average annual rate of 23.3%, while the Biotechs industry saw earnings growing at 13.3% annually. Q32 Bio's return on equity is 71.8%, and it has net margins of 61.9%.
Key information
23.28%
Earnings growth rate
36.73%
EPS growth rate
| Biotechs Industry Growth | -14.59% |
| Revenue growth rate | n/a |
| Return on equity | 71.78% |
| Net Margin | 61.86% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Q32 Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 54 | 33 | 17 | 0 |
| 31 Dec 25 | 54 | 30 | 18 | 0 |
| 30 Sep 25 | 0 | -42 | 17 | 5 |
| 30 Jun 25 | 0 | -52 | 18 | -18 |
| 31 Mar 25 | 0 | -60 | 18 | -10 |
| 31 Dec 24 | 0 | -48 | 18 | 0 |
| 30 Sep 24 | -15 | -61 | 17 | 0 |
| 30 Jun 24 | -13 | -57 | 15 | 23 |
| 31 Mar 24 | -10 | -46 | 12 | 10 |
| 31 Dec 23 | -7 | -54 | 10 | 0 |
| 30 Sep 23 | 12 | -36 | 10 | 0 |
| 31 Dec 22 | 7 | -43 | 10 | 0 |
Quality Earnings: DB0 has a large one-off gain of $11.7M impacting its last 12 months of financial results to 31st March, 2026.
Growing Profit Margin: DB0 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DB0 has become profitable over the past 5 years, growing earnings by 23.3% per year.
Accelerating Growth: DB0 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: DB0 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (21.7%).
Return on Equity
High ROE: DB0's Return on Equity (71.8%) is considered outstanding.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/31 01:37 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Q32 Bio Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Imogen Mansfield | Cantor Fitzgerald & Co. |
| Joseph Pantginis | H.C. Wainwright & Co. |
| Joseph Catanzaro | Mizuho Securities USA LLC |